KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC

被引：0
|
作者：
Cappuzzo, F. [1 ]
Castro Junior, G. [2 ]
Kang, J. H. [3 ]
Wu, Y. L. [4 ]
Brustugun, O. T. [5 ,6 ]
Cheema, P. K. [7 ]
Owonikoko, T. K. [8 ]
Longin, A. S. [9 ]
Duan, J. [10 ]
Caparica, R. [11 ]
Loong, H. H. F. [12 ]
Chan, E. [10 ]
机构：
[1] AUSL Romagna, Hematol Dept, Ravenna, Italy
[2] Univ Sao Paulo, Sao Paulo, SP, Brazil
[3] Catholic Univ Korea, Dept Internal Med, Seoul, South Korea
[4] Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[5] Vestre Viken HF, Dramen Hosp, Sect Oncol, Drammen, Norway
[6] Univ Oslo, Fac Med, Oslo, Norway
[7] William Osler Hlth Syst, Brampton, ON, Canada
[8] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[9] Novartis Pharmaceut, Paris, France
[10] Novartis Pharmaceut, E Hanover, NJ USA
[11] Novartis Pharmaceut, Basel, Switzerland
[12] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 118卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2013
引用
收藏
页码：E14 / E14
页数：1
相关论文
共 27 条
  • [1] KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC.
    Cappuzzo, Federico
    Castro, Gilberto
    Kang, Jin-Hyoung
    Wu, Yi-Long
    Brustugun, Odd Terje
    Cheema, Parneet Kaur
    Owonikoko, Taofeek K.
    Longin, Anne-Sophie
    Boran, Aislyn
    Duan, Jiawei
    Caparica, Rafael
    Loong, Herbert H. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
    Cassier, P.
    Dooms, C.
    Gazzah, A.
    Felip, E.
    Steeghs, N.
    Rohrberg, K. S.
    De Braud, F.
    Solomon, B.
    Schuler, M.
    Tan, D. S.
    Yamamoto, N.
    Loong, H. H. F.
    Cho, B. C.
    Wolf, J.
    Lin, C. C.
    Negrao, M. V.
    Werner, L.
    Cui, X.
    Farago, A. F.
    DeMiguel, M. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : E4 - E5
  • [3] KontRASt-01 update: safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)
    Schuler, M.
    Cassier, P. A.
    Dooms, C.
    Gazzah, A.
    Felip, E.
    Steeghs, N.
    Rohrberg, K. S.
    De Braud, F.
    Solomon, B.
    Tan, D. S.
    Yamamoto, N.
    Loong, H. H.
    Cho, B. C.
    Wolf, J.
    Lin, C. -C
    Negrao, M.
    Werner, L.
    Cui, X.
    Farago, A. F.
    de Miguel, M. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 147 - 148
  • [4] KontRASt-01: Preliminary Safety and Efficacy of JDQ443+TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors
    Negrao, M. V.
    Cassier, P. A.
    Solomon, B.
    Schuler, M.
    Rohrberg, K.
    Cresta, S.
    Dooms, C.
    Tan, D. S. W.
    Loong, H. H-F.
    Amatu, A.
    Assmann, K. Krueger
    Fairchild, L.
    Sansregret, L.
    Fan, L.
    Farago, A. F.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S117 - S118
  • [5] KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)
    Cassier, Philippe Alexandre
    Dooms, Christophe Alfons
    Gazzah, Anas
    Felip, Enriqueta
    Steeghs, Neeltje
    Rohrberg, Kristoffer Staal
    De Braud, Filippo G.
    Solomon, Benjamin J.
    Schuler, Martin H.
    Tan, Daniel Shao-Weng
    Yamamoto, Noboru
    Loong, Herbert H. F.
    Cho, Byoung Chul
    Wolf, Juergen
    Lin, Chia-Chi
    Negrao, Marcelo Vailati
    Werner, Lillian
    Cui, Xiaoming
    Farago, Anna F.
    de Miguel, Maria J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] KontRASt-01: A Phase Ib/II Dose Escalation Study of JDQ443 in Patients with advanced KRAS G12C mutated solid Tumors
    Schuler, M.
    Tan, D. S.
    Shimizu, T.
    Solomon, B.
    Heist, R. S.
    de Miguel, M.
    Gazzah, A.
    Wermke, M.
    Dooms, C.
    Loong, H. H.
    Steeghs, N.
    Felip, E.
    Steuer, C. E.
    Van Cutsem, E.
    Soo, R. A.
    Jaeger, A.
    Kim, J.
    Xu, K.
    Cui, X.
    Burks, H.
    Farago, A. F.
    Cassier, P. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 29 - 29
  • [7] Cost-Effectiveness Analysis of Sotorasib vs. Adagrasib in KRAS G12c-Mutated Previously Treated NSCLC
    Karim, N.
    Waterhouse, D.
    Jones, S.
    Stollenwerk, B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S719 - S720
  • [8] Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC
    Hochmair, Maximilian J.
    Vermaelen, Karim
    Mountzios, Giannis
    Carcereny, Enric
    Dooms, Christophe
    Lee, Se-Hoon
    Morocz, Eva
    Kato, Terufumi
    Ciuleanu, Tudor-Eliade
    Dy, Grace K.
    Parente, Barbara
    O'Byrne, Kenneth J.
    Chu, Quincy S.
    De Castro Junior, Gilberto
    Girard, Nicolas
    Snyder, Wendy
    Tran, Qui
    Kormany, William
    Houk, Brett
    Mehta, Bhakti
    Curioni-Fontecedro, Alessandra
    EUROPEAN JOURNAL OF CANCER, 2024, 208
  • [9] Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC
    Waterhouse, D. M.
    Rothschild, S.
    Dooms, C.
    Mennecier, B.
    Bozorgmehr, F.
    Majem, M.
    van den Heuvel, M.
    Linardou, H.
    Chul-Cho, B.
    Roberts-Thomson, R.
    Okamoto, I.
    Blais, N.
    Schvartsman, G.
    Holmskov, K.
    Chmielewska, I.
    Forster, M.
    Stollenwerk, B.
    Obiozor, C. C.
    Wang, Y.
    Novello, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S37 - S38
  • [10] A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors
    Ramalingam, Suresh
    Fakih, Marwan
    Strickler, John
    Govindan, Ramaswamy
    Li, Bob T.
    Goldberg, Sarah
    Gandara, David
    Burns, Timothy
    Barve, Minal
    Shu, Catherine
    Frank, Richard
    Sohal, Davendra
    Jafarinasabian, Pegah
    Dai, Tian
    Mather, Omar
    Hong, David
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
123